Abstracts tagged "alternative medicine"

Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Madison Grinnell¹, Kristin Wipfler ², Alexis Ogdie ³ and Kaleb Michaud ⁴, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…
Abstract Number: 1709 • 2018 ACR/ARHP Annual Meeting
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Lindsey Warner and Shazia Beg, University of Central Florida College of Medicine, Orlando, FL
Background/Purpose: Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to…
Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Majid Zeidi^1,2, Peter B Chansky^1,2 and Victoria P Werth^3,4, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
Abstract Number: 18 • 2015 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Facilitates TAK1 Nuclear Translocation and Its Interaction with p300 to Inhibit Histone Acetylation in Human RA Synovial Fibroblasts
Anil Singh^1,2, Mukesh Chourasia³ and Salahuddin Ahmed⁴, ¹Department of Pharmaceutical Science, Washington State University, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, Spokane, WA
Background/Purpose: TAK1 is one of the most important proteins in IL-1β signaling cascade that mediates downstream p38/JNK and NF-κB activation. In the present study, we…
Abstract Number: 19 • 2015 ACR/ARHP Annual Meeting
Pentagalloyl Glucose (PGG) Exhibits Anti-Rheumatic Activity in Human RA Synovial Fibroblasts and Rat Adjuvant-Induced Arthritis
Sadiq Umar¹, Gates Roe¹, Sabrina Fechtner¹ and Salahuddin Ahmed², ¹Department of Pharmaceutical Science, Washington State University College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, Spokane, WA
Background/Purpose: Pentagalloyl glucose (PGG) is a natural polyphenolic and water-soluble gallotannin that exhibits anti-cancer and anti-inflammatory activities. In the present study, we evaluated the efficacy…
Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Basmah Jalil¹, Wilmer Sibbitt Jr.², Romy Cabacangun³, Clifford Qualls⁴, Arthur Bankhurst⁵ and Roderick Fields⁶, ¹Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, ³Rheumatology, UNM, Albuquerque, NM, ⁴Biostatistics, UNM, Albuquerque, NM, ⁵Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁶Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
Abstract Number: 2254 • 2013 ACR/ARHP Annual Meeting
Complementary and Alternative Medicine in Rheumatoid Arthritis – Persistently High Use Over the Past Decade Despite Advent of Biologics
Dana DiRenzo^1,2, Haiyan Sun³, H. Lester Kirchner³ and Eric D. Newman⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ⁴Department of Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Complementary and Alternative Medicine (CAM) is commonly used when traditional medicine cannot reliably alter the disease. Over the past decade, rheumatoid arthritis (RA) treatment…
Abstract Number: 1105 • 2013 ACR/ARHP Annual Meeting
New and Not Improved? The Efficacy Of FMS Medications
Robert S. Katz¹, Hannah Bond², Lauren Kwan², Jessica L. Polyak² and Susan Shott³, ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: A wide variety of medications are used to treat FMS, with an equally wide variety of opinions about their efficacy. We asked FMS…
Abstract Number: 1556 • 2012 ACR/ARHP Annual Meeting
The Effect of Ginger Therapy On Symptoms of Osteoarthritis: An Open Pilot Study
Tessa Therkleson, Nursing, Edith Cowan University, Perth, Australia
Background/Purpose: Osteoarthritis (OA) is a painful, progressive disease of synovial joints characterised by deterioration of cartilage and bone and inflammation. Osteoarthritis of the knee and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].